Terms: = Liver cancer AND GATA3, HDR, 2625, ENSG00000107485, MGC5445, MGC5199, MGC2346 AND Treatment
54 results:
1. Transcriptomic screening of novel targets of sericin in human hepatocellular carcinoma cells.
Jantaravinid J; Tirawanchai N; Ampawong S; Kengkoom K; Somkasetrin A; Nakhonsri V; Aramwit P
Sci Rep; 2024 Mar; 14(1):5455. PubMed ID: 38443583
[TBL] [Abstract] [Full Text] [Related]
2. Role of diffusion-weighted imaging in response prediction and evaluation after high dose rate brachytherapy in patients with colorectal liver metastases.
Karim S; Seidensticker R; Seidensticker M; Ricke J; Schinner R; Treitl K; Rübenthaler J; Ingenerf M; Schmid-Tannwald C
Radiol Oncol; 2024 Mar; 58(1):33-42. PubMed ID: 38378033
[TBL] [Abstract] [Full Text] [Related]
3. CT-guided High-Dose-Rate Brachytherapy versus Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma.
Auer TA; Müller L; Schulze D; Anhamm M; Bettinger D; Steinle V; Haubold J; Zopfs D; Pinto Dos Santos D; Eisenblätter M; Gebauer B; Kloeckner R; Collettini F
Radiology; 2024 Feb; 310(2):e232044. PubMed ID: 38319166
[TBL] [Abstract] [Full Text] [Related]
4. Comprehensive analysis of cancer of unknown primary and recommendation of a histological and immunohistochemical diagnostic strategy from China.
Ren M; Cai X; Jia L; Bai Q; Zhu X; Hu X; Wang Q; Luo Z; Zhou X
BMC Cancer; 2023 Dec; 23(1):1175. PubMed ID: 38041048
[TBL] [Abstract] [Full Text] [Related]
5. Aberrant expression of gata3 in metastatic adenocarcinoma of the prostate: an important pitfall.
Lobo J; Tenace NP; Cañete-Portillo S; Carneiro I; Henrique R; Lucianò R; Harik LR; Magi-Galluzzi C
Histopathology; 2024 Feb; 84(3):507-514. PubMed ID: 37965687
[TBL] [Abstract] [Full Text] [Related]
6. Balance of gata3 and Ramp2 in hepatocytes regulates hepatic vascular reconstitution in postoperative liver regeneration.
Wang B; Shen H; Wei Y; Liu F; Yang Y; Yu H; Fu J; Cui X; Yu T; Xu Y; Liu Y; Dong H; Shen F; Zhou W; Liu H; Chen Y; Wang H
J Hepatol; 2024 Feb; 80(2):309-321. PubMed ID: 37918568
[TBL] [Abstract] [Full Text] [Related]
7. Ovarian Mesonephric-Like Adenocarcinoma With Recurrent liver Metastases: A Case Report with Analysis of Therapeutic Molecular Targets.
Sugitani A; Ogawa A; Yoshida H; Kobayashi-Kato M; Kikkawa N; Tanase Y; Uno M; Ishikawa M; Kato T
Int J Surg Pathol; 2024 May; 32(3):578-585. PubMed ID: 37345348
[TBL] [Abstract] [Full Text] [Related]
8. A case report of pulmonary hepatoid adenocarcinoma: promoting standardized diagnosis and treatment of the rare disease.
Xu K; Gao J; Feng L; Fang Y; Tang X
Front Immunol; 2023; 14():1203876. PubMed ID: 37292208
[TBL] [Abstract] [Full Text] [Related]
9. Prevention of radiation-induced liver toxicity after interstitial hdr brachytherapy by pentoxifylline and ursodeoxycholic acid: patient compliance and outcome in a randomized trial.
Damm R; Wybranska J; Hass P; Walke M; Omari J; Pech M; Seidensticker R; Ricke J; Seidensticker M
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9043-9049. PubMed ID: 37166579
[TBL] [Abstract] [Full Text] [Related]
10. Clinicopathological Features and Prognosis of Gastrointestinal Metastases From Breast Carcinoma: A Clinicopathological Study of 22 Patients.
Wang S; Li W; Li S; Liu X; Zhang L; Hao C; Meng W; Zhao W; Tong Z
Int J Surg Pathol; 2023 Sep; 31(6):1075-1084. PubMed ID: 36803140
[No Abstract] [Full Text] [Related]
11. Percutaneous high-dose-rate interstitial brachytherapy for non-resectable, chemo resistant malignant lesion of lung and liver.
Yadawa N; Shahi UP; Mandal A; Verma A; Kumari K; Aggrawal LM; Jaiswal I; Mourya A; Jaiswal AK; Srivastava P
J Cancer Res Ther; 2023 Jan; 19(Suppl 2):S807-S814. PubMed ID: 38384060
[TBL] [Abstract] [Full Text] [Related]
12. Cytomorphology, immunoprofile, and clinicopathologic correlation of metastatic prostatic carcinoma.
Lin X; Shi Q; Yang XJ
Hum Pathol; 2022 Dec; 130():36-46. PubMed ID: 36244466
[TBL] [Abstract] [Full Text] [Related]
13. TNF-α Indicates Radiation-induced liver Injury After Interstitial High Dose-rate Brachytherapy.
Damm R; Pech M; Haag F; Cavalli P; Gylstorff S; Omari J; Seidensticker R; Ricke J; Seidensticker M; Relja B
In Vivo; 2022; 36(5):2265-2274. PubMed ID: 36099091
[TBL] [Abstract] [Full Text] [Related]
14. Correlation of chemokines and growth factors with radiation-induced liver injury after interstitial high dose rate (hdr) brachytherapy of liver metastases.
Damm R; Pech M; Cavalli P; Haag F; Gylstorff S; Omari J; Thormann M; Seidensticker R; Ricke J; Seidensticker M; Relja B
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2815-2826. PubMed ID: 35596772
[TBL] [Abstract] [Full Text] [Related]
15. Poorly Differentiated Scrotal Carcinoma With Apocrine Immunophenotype.
Kamanda S; Epstein JI; Osunkoya AO; Cimino-Mathews A; Argani P; Sangüeza M; Plaza JA; Matoso A
Am J Dermatopathol; 2022 Apr; 44(4):260-266. PubMed ID: 34726185
[TBL] [Abstract] [Full Text] [Related]
16. Integrated multi-omics profiling of high-grade estrogen receptor-positive, HER2-negative breast cancer.
Wang K; Li L; Franch-Expósito S; Le X; Tang J; Li Q; Wu Q; Bassaganyas L; Camps J; Zhang X; Li H; Foukakis T; Xiang T; Wu J; Ren G
Mol Oncol; 2022 Jun; 16(12):2413-2431. PubMed ID: 34146382
[TBL] [Abstract] [Full Text] [Related]
17. A review of dosimetric impact of implementation of model-based dose calculation algorithms (MBDCAs) for hdr brachytherapy.
Yousif YAM; Osman AFI; Halato MA
Phys Eng Sci Med; 2021 Sep; 44(3):871-886. PubMed ID: 34142317
[TBL] [Abstract] [Full Text] [Related]
18. Validation of the collapsed cone algorithm for hdr liver brachytherapy against Monte Carlo simulations.
Duque AS; van Wagenberg T; Seidensticker M; Streitparth F; Walter F; Parodi K; Verhaegen F; Ricke J; Belka C; Paiva Fonseca G; Corradini S; Landry G
Brachytherapy; 2021; 20(4):936-947. PubMed ID: 34001415
[TBL] [Abstract] [Full Text] [Related]
19. Comparison of liver exposure in CT-guided high-dose rate (hdr) interstitial brachytherapy versus SBRT in hepatocellular carcinoma.
Walter F; Nierer L; Rottler M; Duque AS; Weingandt H; Well J; Shpani R; Landry G; Seidensticker M; Streitparth F; Ricke J; Belka C; Corradini S
Radiat Oncol; 2021 May; 16(1):86. PubMed ID: 33957941
[TBL] [Abstract] [Full Text] [Related]
20. Radiotherapeutic treatment options for oligotopic malignant liver lesions.
Wust P; Beck M; Dabrowski R; Neumann O; Zschaeck S; Kaul D; Modest DP; Stromberger C; Gebauer B; Ghadjar P
Radiat Oncol; 2021 Mar; 16(1):51. PubMed ID: 33726751
[TBL] [Abstract] [Full Text] [Related]
[Next]
